In-111-DTPA-octreotide scan (A) demonstrates recurrent mesenteric nodule (arrow) on the anterior view in a patient with a mid-gut carcinoid tumor resected 5 years previously, with no other tumor seen ...
SAN FRANCISCO -- Adding a radioligand to standard therapy almost tripled median progression-free survival (PFS) in untreated high-grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a ...
Interim results from a phase 3 trial supported the use of the radioligand therapy 177 Lu-DOTATATE (Lutathera) as first-line therapy to treat high-grade gastroenteropancreatic neuroendocrine tumors.
Credit: Getty Images. The NETTER-2 trial included patients with newly diagnosed SSTR-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors. First-line treatment with lutetium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results